289 filings
Page 14 of 15
8-K
ouflecrwtqx1uqi16gc
12 Jul 17
Other Events
12:00am
8-K
a2rzuosm0w
30 Jun 17
Other Events
12:00am
8-K
6jv2eoysb0b1t9nh80
27 Jun 17
Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer
12:00am
8-K
dbs vw4bult5ymd
13 Jun 17
Moleculin Announces Preparation to File an IND with the FDA for WP1220 for Treatment of Cutaneous T-Cell Lymphoma
12:00am
8-K
3l451h ebi6
31 May 17
Entry into a Material Definitive Agreement
12:00am
8-K
8q2acts2ekjzjw zoi15
23 May 17
Moleculin Biotech Issues Shareholder Update on FDA Designation of Orphan Drug and IND Status for Annamycin
12:00am
8-K
btdnku7ht5xbdih31dn2
19 May 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
5ovmq
16 May 17
Results of Operations and Financial Condition
12:00am
8-K
k9pm5o
17 Apr 17
Moleculin Biotech Appoints Theradex Systems as CRO to Manage Phase I/II Annamycin Trial
12:00am
8-K
8hh143gbf6rgypy1valj
3 Apr 17
Recently Received Orphan Drug Designation for Annamycin
12:00am
8-K
c0zm6
22 Mar 17
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
12:00am
8-K
vh1 br0glx
14 Mar 17
Other Events
12:00am
8-K
gg86x3 gnaz
28 Feb 17
Regulation FD Disclosure
12:00am
8-K
15hambbsg6ru
23 Feb 17
Changes in Registrant's Certifying Accountant
12:00am
8-K
i6gf7t0k3ay
9 Feb 17
Moleculin Announces Pricing of $5 Million Underwritten Public Offering
12:00am
8-K
iz7lwk
21 Nov 16
Results of Operations and Financial Condition
12:00am
8-K
yjscg0hgrp6i
18 Nov 16
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
12:00am
8-K
xlbf nei3bpse9
21 Oct 16
Regulation FD Disclosure
12:00am
8-K
7qjmek
13 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
ywspdqf
11 Oct 16
Moleculin Announces Accelerated Plan for Clinical Trial Drug Production
12:00am